The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus
The α-glucosidase inhibitor miglitol decreases glucose fluctuations and inflammatory cytokine gene expression in peripheral leukocytes of Japanese patients with type 2 diabetes mellitus
复制标题
DOI：
10.1016/j.metabol.2010.06.006
复制
发表时间：
2010-12-01
影响因子：
9.8
通讯作者：
Goda, Toshinao
中科院分区：
文献类型：
--
作者：
Osonoi, Takeshi;Saito, Miyoko;Goda, Toshinao
在这项研究中，我们研究了2型糖尿病患者从阿卡波糖或伏糖糖转换为米格列醇3个月对外周血白细胞炎症因子/细胞因子样因子基因表达和血糖波动的影响。我们招募了47名日本2型糖尿病患者，年龄26至81岁，血红蛋白A（1c）水平在6.5%至7.9%之间，接受最高批准剂量的阿卡波糖（100mg /餐）或福格糖（0.3 mg /餐）联合胰岛素或磺脲类药物治疗。他们先前的a-葡萄糖苷酶抑制剂改为中剂量的米格列醇（每餐50毫克），新的治疗持续3个月。43名患者完成了为期3个月的研究并进行了分析。改用米格列醇3个月对血红蛋白A（1c）、空腹血糖、甘油三酯、总胆固醇或c反应蛋白水平没有影响，也没有低血糖症状以外的不良事件。转换后，低血糖症状和血糖波动明显改善。切换到米格列醇后，外周白细胞白介素-1 β、肿瘤坏死因子- α和S100a4/6/9/10/11/12基因的表达以及血清肿瘤坏死因子- α蛋白水平均受到抑制。米格列醇比其他α -葡萄糖苷酶抑制剂更能降低2型糖尿病患者血糖波动和外周白细胞炎症因子/细胞因子样因子的基因表达，且不良反应更少。(C) 2010爱思唯尔公司版权所有。
In this study, we examined the effects of switching from acarbose or voglibose to miglitol in type 2 diabetes mellitus patients for 3 months on gene expression of inflammatory cytokines/cytokine-like factors in peripheral leukocytes and on glucose fluctuations. We enrolled 47 Japanese patients with type 2 diabetes mellitus, aged 26 to 81 years, with hemoglobin A(1c) levels ranging from 6.5% to 7.9% and who were treated with the highest approved dose of acarbose (100 mg per meal) or voglibose (0.3 mg per meal) in combination with insulin or sulfonylurea. Their prior a-glucosidase inhibitors were switched to a medium dose of miglitol (50 mg per meal), and the new treatments were maintained for 3 months. Forty-three patients completed the 3-month study and were analyzed. The switch to miglitol for 3 months did not affect hemoglobin A(1c), fasting glucose, triglycerides, total cholesterol, or C-reactive protein levels, or adverse events other than hypoglycemia symptoms. Hypoglycemia symptoms and glucose fluctuations were significantly improved by the switch. The expression of interleukin-1 beta, tumor necrosis factor-alpha, and S100a4/6/9/10/11/12 genes in peripheral leukocytes, and the serum tumor necrosis factor-alpha protein levels were suppressed by switching to miglitol. Miglitol reduces glucose fluctuations and gene expression of inflammatory cytokines/cytokine-like factors in peripheral leukocytes of type 2 diabetes mellitus patients more than other alpha-glucosidase inhibitors and with fewer adverse effects. (C) 2010 Elsevier Inc. All rights reserved.